Great Deal! Get Instant $10 FREE in Account on First Order + 10% Cashback on Every Order Order Now

Financial Reporting

1 answer below »
ACCM4300_T2_2021_Assessment_3
Page 1 Kaplan Business School Assessment 3 Outline
Assessment 3 Information

Subject Code: ACCM4300
Subject Name: Financial Reporting
Assessment Title: Statement of Advice
Assessment Type: Provision of advice on accounting issues
Word Count 1,500 words maximum (Do not include the title page or reference list in
the word count)
Weighting: 30 %
Total Marks: 30
Submission: Via Turnitin on MyKBS
Due Date: Tuesday of Week 13 at 19:55 (AEST)
Your Task
You are required to prepare a business letter to answer key accounting issues in regard to an
acquisition analysis of a wholly owned subsidiary and various inter-company transactions.

This is an individual assessment.

Assessment Description
Assume that you are a graduate accountant working for Brook Rivers, a public accounting firm
situated at 102 Goulburn Street, Sydney, NSW 2000. The Manager of your firm, Mr. Steve
Kaplan, has asked you to prepare a statement of advice in response to an email received from a
client, Ms. Anna Sunana, the Managing Director of Ferengi Ears Ltd, raising several accounting
issues. Please refer to the email on the next page.

The maximum length for the body of the letter is 1,500 words. You should address all the
technical issues and discussion in your advice, followed by a Reference List.

• Part A: Technical component 20% - This mark covers the technical content of your advice
and the explanation of each of the issues, the calculations and journal entries (where
applicable).
• Part B: Communication Skills 10% - This mark covers the generic skills of writing; layout,
clear meaning, structure and organisation, appropriate tone and grammar, spelling, and
punctuation throughout the whole assignment. It also includes referencing.

Case Study

Ferengi Ears Ltd, a publicly traded company listed on the ASX, is a global leader in the
development, manufacturing, and commercialisation of implantable hearing solutions. With shares
trading at $9.20 each on 1 July 2022, the company has invested consistently in research and
development to enhance and expand their product portfolio. As a result, thousands of individuals
worldwide now benefit from Ferengi Ears implants that significantly improve their quality of life and
communication abilities. Under the leadership of our new CEO, Ferengi Ears Ltd has initiated a
strategy of providing personalised solutions and comprehensive support to patients. This approach
includes the acquisition of Precisi Medical Ltd, whose clinics assist in diagnosing patients’ hearing
equirements, ensuring optimal outcomes for those with hearing loss.

Ferengi Ears Ltd’s incremental bo
ow rate stands at 9%, while the corporate tax rate is 30%.
Page 2 Kaplan Business School Assessment 3 Outline

Draft a business letter in reply and make sure you reference any relevant sources relating to your
advice, for example, AASBs, Corporations Act, and relevant sources. See the email below.

Re: Accounting Issues for year ended 30 June 2024
From: Anna Sunana ( XXXXXXXXXX)
Sent: 2 July 2024
To: Steve Kaplan (S. XXXXXXXXXX)


Dear Steve,

I am reaching out to you for assistance as our Chief Accountant is cu
ently on long service
leave. I need to understand the accounting implications of our recent takeover of Precisi Medical
Ltd so that I can present the consolidated financial statements to the Board of directors and
espond to any further questions they may have concerning the accounts for the year ended 30
June XXXXXXXXXXAs I do not have any accounting experience, please explain the principles and
concepts for me in simple language.

As you know, we have recently acquired 100% of the issued shares of Precisi Medical Ltd on 1
July 2022 on a cum-div basis. Precisi Medical Ltd was established in 2010, specialising in the
provision of health advice to customers. The terms of the acquisition were that shareholders of
Precisi Medical Ltd would receive $1.10 cash per share plus one share in Ferengi Ears Ltd for
every four ordinary shares of Precisi Medical Ltd. The cash would be payable to shareholders in
two instalments, with half payable at the date of acquisition and the balance payable on 1 July
2023.

The statement of financial position of Precisi Medical Ltd as at 1 July 2022 included the following
information:

Cash $20,000
Accounts receivable (net) 42,000
Inventories 5,000
Property, plant and equipment (net) 228,000
Goodwill 10,000
$305,000
Accounts payable $5,000
Wages payable 4,000
Dividend payable 11,000
Loan payable 100,000
Share capital - $1 share 60,000
Retained earnings 125,000
$305,000

All the assets of Precisi Medical Ltd were recorded at fair value except for some equipment and
inventories whose ca
ying amounts were each $2,100 less than the fair values. The equipment
consisted of audiomebots used to test for hearing loss. Due to rapid changes in technology, it
was estimated that the useful life of the equipment was only a further three years. It was also
discovered that Precisi Medical Ltd had developed a business magazine containing health advice
for consumers. This magazine was widely sought after. Ferengi Ears Ltd placed a value of
$5,000 on the masthead of this magazine. The intangible asset was not recognised by Precisi
Medical Ltd at acquisition date as it was internally generated and was considered to have an
indefinite life. On 1 June 2022, a major competitor sued Precisi Medical Ltd for alleged damaging
mailto: XXXXXXXXXX
Page 3 Kaplan Business School Assessment 3 Outline
statements made in the magazine, and the court case was in progress at the date of acquisition.
No monetary amount was disclosed in the financial statements, but the company’s lawyers
elieved that the probable payout to settle the case was $18,000. The case has yet to be settled.

One of the key rules of acquisition is to never spend more for an acquisition than you have to.
Our Accounts Clerk prepared an acquisition analysis and determined a gain on bargain purchase
of $119,000 (calculated as $66,000 cash paid minus the subsidiary’s equity acquired of
$185,000) to be reported as income in the accounts. Can you check that this right and help me
with the acquisition analysis? It was a fantastic bargain and we managed to sell all of Precisi
Medical Ltd’s existing inventories to one of our main customers within the first month of acquiring
the company, resulting in significant profits for our group.

What journal entries (if any) do I need to make for 30 June 2024 to prepare the consolidated
financial statements? Please show all workings and explain each journal entry, as I need to be
able to respond to questions from the Board of Directors.

Prior to going on long service leave, The Chief Accountant identified two inter-company
transactions for further consideration when preparing the consolidated accounts. Specific details
of these transactions are as follows:

1. On the 25th of June 2024, we sold some of our older hearing implants from our
Freedom range of stock costing $30,000 to Precisi Medical Ltd for $50,000 on
credit, recognizing a profit of $20,000 from the sale. At year-end, 90% of these
goods had been sold by Precisi Medical Ltd to external entities at a 20% markup.
Is there anything else we need to do? Please provide any necessary journal
entries.


2. On 1 January 2023, Ferengi Ears Ltd sold some diagnostic equipment on
favorable terms to Precisi Medical Ltd for $42,000. Ferengi Ears Ltd had originally
paid $85,000 for this asset, and at the time of sale had charged accumulated
depreciation of $37,000. This asset is to be depreciated on a straight-line basis at
10% p.a. on cost and it is still on hand with Precisi Medical Ltd at 30 June 2024.
Please explain what I need to do with this transaction and show any journal entries
necessary for the preparation of Consolidated financial statements.


Please respond by letter (not email) as I would like to present this to the Board. I look forward to
hearing from you shortly.


Regards,



Anna Sunana
Managing Director, Ferengi Ears Ltd
578 Chester Road,
Melbourne Vic 3000
Page 4 Kaplan Business School Assessment 3 Outline

Assessment Instructions

The assignment will need to be submitted electronically through MyKBS – use the link under
“Assessments”.
Please refer to the Assessment Marking Guide to assist you in completing all the assessment
criteria.

Referencing
Any sources that you use need to be acknowledged in order to avoid plagiarism. Information
on referencing can be found at the Kaplan website ‘s Academic Success Centre using the
following address: (https:
elearning.kbs.edu.au/mod/page/view.php?id=245257).

In‐Text Referencing and the Reference List
Sources of information must be cited both in the body of the text (in‐text referencing) and the
end of the assignment (reference list). Failure to do so will result in penalties. Remember that
when referencing an Annual Report, it is a corporate document that does not have a
particular author but it will still require referencing any time you use information from it. Any
other documents or books or other references you use will also require referencing.

Please note
Any work which has been copied or shared between students will result in a Fail grade for all
students concerned. Therefore, please make sure that the answer to this assignment is your
work and not copied or bought from any source. In completing this assignment make sure
you follow the guidelines for assignments especially those relating to the presentation of
written work, late assignment policy and academic integrity.
Page 5 Kaplan Business School Assessment 3 Outline



Important Study Information

Academic Integrity Policy

KBS values academic integrity. All students must understand the meaning and consequences
of cheating, plagiarism and other academic offences under the Academic Integrity and
Conduct Policy.

• What is academic integrity and misconduct?
• What are the penalties for academic misconduct?
• What are the late penalties?
• How can I appeal my grade?

The answers to these questions can be accessed at https:
www.kbs.edu.au/about-us/school-
policies.


Length Limits for Assessments

Penalties may be applied for assessment submissions that exceed prescribed limits.


Study Assistance

Students may seek study assistance from their local Academic Learning Advisor or refer to
the resources on the MyKBS Academic Success Centre page. Further details can be
accessed at https:
elearning.kbs.edu.au/course/view.php?id=1481









Answered 2 days After Jun 02, 2024

Solution

Shubham answered on Jun 05 2024
3 Votes
Re: Accounting Issues for year ended 30 June 2024
From: Anna Sunana ([email protected])
Sent: 2 July 2024
To: Steve Kaplan ([email protected])
Dear Ms. Sunana,
Thank you for raising queries regarding recent acquisition of Precisi Medical Ltd and accounting implications. I have provided detailed explanation for addressing each concern and this will help in ensuring clarity and compliance that is relevant to accounting standards.
Acquisition Analysis and Initial Journal Entries
Facts and Accounting Topic
Ferengi Ears Ltd has completed acquisition of 100% of issued shares of Precisi Medical Ltd on 1 July 2022. The terms of acquisition have been specified for every shareholder of Precisi Medical Ltd. Every shareholder will receive $1.10 in cash per share that is payable in two instalments. It includes instalment that are 50% at the date of acquisition and remaining 50% on 1 July 2023.
As per statement of Precisi Medical Ltd of financial position on 1 July 2022 the total net assets is $185,000. This includes detailed examination that describes ca
ying amounts of certain assets that includes equipment and inventories that is considered as $2,100 each. The additional considerations include lawsuit with estimated settlement cost of $18,000. It is internally generated magazine masthead that is valued at $5,000. The adjustments is important for accurate acquisition analysis and consolidation in financial statements.
Relevant Legislation and Accounting Standards
AASB 3 Business Combinations
AASB 3 Business Combinations describes about accounting treatment for business combinations. The standard ensures that acquirer should identify and measure fair value of the identifiable assets, liabilities and any non-controlling interests of acquiree at acquisition date (Bradbury, Mehnaz and Scott, 2022). The primary objective is to provide transparent and comparable information about nature and financial effects of business combinations.
In AASB 3, the acquisition method should be applied and this includes several steps:
1. Identifying the Acquirer: The entity that obtains control of acquiree.
2. Determining the Acquisition Date: The date on which acquirer obtains control of acquiree.
3. Recognizing and Measuring Identifiable Assets Acquired, Liabilities Assumed and Non-Controlling Interests in the Acquiree: All identifiable assets and liabilities that are are recorded at fair values at acquisition date.
4. Recognizing and Measuring Goodwill or a Gain from a Bargain Purchase: Goodwill is measured as excess of consideration transfe
ed over net identifiable assets acquired. If net assets exceed consideration transfe
ed, the gain on bargain purchase is recognized.
AASB 10 Consolidated Financial Statements
AASB 10 Consolidated Financial Statements can be help in setting requirements for preparation and presentation of consolidated financial statements. Control is defined as power to govern financial and operating policies of entity for obtaining benefits from activities.
The key principles of AASB 10 include:
1. Definition of Control: The investor controls include investee that has exposure and rights to variable returns from involvement with investee. It has the ability to affect returns through power over investee.
2. Requirement to Consolidate: The parent company must consolidate all subsidiaries and present financial information about single economic entity.
3....
SOLUTION.PDF

Answer To This Question Is Available To Download

Related Questions & Answers